Diarrhea and Constipation Drug Development Pipeline Review, 2018
- Pages: 93
- Published: July 2018
- Report Code: GBIHC041IDB
This report provides an overview of the pipeline landscape for diarrhea and constipation. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for diarrhea and constipation, and features dormant and discontinued products.
Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. There are 54 products in development for this indication and molecular targets present in the pipeline landscape include cystic fibrosis transmembrane conductance regulator and glucagon like peptide 2 receptor.
Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting.
The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. There are 25 products in development for this indication and molecular targets present in the pipeline landscape include 5-hydroxytryptamine receptor 4 and heat stable enterotoxin receptor.
Companies operating in this pipeline space include Synthetic Biologics, Allergan and Ardelyx.
Scope
– Which companies are the most active within each pipeline?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Companies mentioned
Aegis Therapeutics LLC
Akthelia Pharmaceuticals Ltd
Albireo Pharma Inc
Allergan Plc
Ardelyx Inc
AzurRx BioPharma Inc
Bharat Biotech Ltd
Braintree Laboratories Inc
Chongqing Zhifei Biological Products Co Ltd
Cosmo Pharmaceuticals NV
Diarrhea
DiscoveryBiomed Inc
Dong-A ST Co Ltd
EA Pharma Co Ltd
Ferring International Center SA
GP Pharm SA
Ironwood Pharmaceuticals Inc
Johnson & Johnson
Kuhnil Pharmaceutical Co Ltd
MallInckrodt Plc
Metacrine Inc
Miyarisan Pharmaceutical Company Ltd
Napo Pharmaceuticals Inc
NGM Biopharmaceuticals Inc
Nippon Shinyaku Co Ltd
Novartis AG
Pfizer Inc
Prokarium Ltd
Protagonist Therapeutics Inc
RaQualia Pharma Inc
RedHill Biopharma Ltd
RxBio Inc
Sanwa Kagaku Kenkyusho Co Ltd
Scandinavian Biopharma Holding AB
SK Biopharmaceuticals Co Ltd
Sublimity Therapeutics Ltd
Sumitomo Dainippon Pharma Co Ltd
Summit Therapeutics Plc
Synthetic Biologics Inc
Syntiron LLC
Tasly Pharmaceutical Group Co Ltd
Vanda Pharmaceuticals Inc
Wuhan Institute of Biological Products Co Ltd
Yuhan Corp
Zealand Pharma AS
Zensun (Shanghai) Sci & Tech Co Ltd
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.